ライフサイエンスコーパス: GABA(A) agonist

1 of a D1 antagonist, an AMPA antagonist, or a GABAA agonist.

2 usions of fluorophore-conjugated muscimol, a GABAA agonist.

3 nists reduced the postsynaptic response to a GABA(A) agonist.

4 Microinjections of a GABA(A) agonist (0, 25, 75, and 225 ng/0.5 microl muscim

5 A GABA(A0r) agonist but not GABA(A) agonists altered the myopic refraction of goggle

6 sing localized microinfusions of muscimol (a GABAA agonist) and susceptibility to motor seizures in r

7 We injected muscimol, a GABA(A) agonist, and manganese, a magnetic resonance ima

8 the amygdala (BLA) by injecting muscimol, a GABAA agonist, before or after preexposure reduced this

9 Because muscimol, a GABA(A) agonist, blocked both spontaneous motoneuron bur

10 PP, an NMDA receptor antagonist, and THIP, a GABA(A) agonist, blocked the acute response and the indu

11 However, a preinjection of muscimol (a GABA(A) agonist) completely blocked the active sleep-ind

12 Muscimol, a GABA(A) agonist, disrupted picrotoxin self-infusion, but

13 ific neuronal inhibition in this region with GABA(A) agonists disrupts sleep architecture.

14 tivation of sleep-promoting circuitry or the GABAA agonist Gaboxadol.

15 Using zolpidem (Ambien), a short-acting GABAA agonist hypnotic, we show increased sleep spindle

16 alpha-2 adrenergic agonist) and muscimol (a GABAa agonist) induce an inhibition of PS.

17 Only a GABA(A) agonist induced a myopic refraction.

18 Bilateral injections of muscimol, a GABAA agonist, into the mPFC significantly decreased the

19 Microinjection of the GABA(A) agonist isoguvacine into the NTS increased mean

20 The effects of the GABAA agonist, isoguvacine, on NMDA-induced burst firing

21 it was reversibly abolished by the selective GABAA agonist, isoguvacine.

22 tion of the GABA(A) receptors, with specific GABA(A) agonists, leads to cellular excitation.

23 imol, a gamma amino butyric acid receptor-A (GABA(A)) agonist, mitigates the AD syndrome and vascular

24 Infusion of the GABA(A) agonist muscimol (0.1 microg) into the deep SC/M

25 ar-potentiated startle after infusion of the GABA(A) agonist muscimol (0.1 microg/0.5 microl).

26 of repeated microinjections (100 nl) of the GABA(A) agonist muscimol (1 mm), induced the following:

27 bited bilaterally with microinjection of the GABA(A) agonist muscimol (100 pmol in 100 nl per side).

28 0.5 or 1 microg) or bicuculline (20 ng), the GABA(A) agonist muscimol (15 ng) or vehicle.

29 Concurrent temporary inactivation with the GABA(A) agonist muscimol (5-20 ng/0.25 microl) of the do

30 at transient inactivation of amygdala by the GABA(A) agonist muscimol (MUS), specifically during the

31 ting a single barrel by iontophoresis of the GABA(A) agonist muscimol abolished the representation of

32 s of etomidate were mimicked by the specific GABA(A) agonist muscimol and blocked by the specific ant

33 ther inhibition of cells in the PVT with the GABA(A) agonist muscimol could alter food intake in non-

34 n break point and correct lever-presses; the GABA(A) agonist muscimol did not affect breakpoint or le

35 tioning was examined further by applying the GABA(A) agonist muscimol directly into the amygdala eith

36 Inhibiting activity with the GABA(A) agonist muscimol impaired DMTP.

37 Microinjection of the GABA(A) agonist muscimol in the rostral medial accumbens

38 ugh a series of reversible injections of the GABA(A) agonist muscimol in these nuclei in parkinsonian

39 Injections of the GABA(A) agonist muscimol into the AcbSh greatly increase

40 Infusions of the GABA(A) agonist muscimol into the LS prior to testing si

41 ions of CGS 21680 into the accumbens and the GABA(A) agonist muscimol into ventral pallidum (i.e., "d

42 effects caused by application of either the GABA(A) agonist muscimol or the AMPA antagonist CNQX low

43 Cl-]i was accompanied by an inability of the GABA(A) agonist muscimol to cause Cl- influx.

44 retreated the DLSC of four macaques with the GABA(A) agonist muscimol to determine whether this treat

45 We used the GABA(A) agonist muscimol to functionally inactivate thes

46 GABA and the GABA(A) agonists muscimol and isoguvacine enhanced isola

47 usion of the gamma-aminobutyric acid type A (GABA(A)) agonist muscimol and traced CS axons from the i

48 Focal pretreatment of MD with the GABAA agonist muscimol (190 pmol) protected against seiz

49 We infused the GABAA agonist muscimol (4.4 nmol/side) or vehicle into l

50 Iontophoresis of the GABAA agonist muscimol (MUS) into the lateral PB extende

51 The inhibitory effects of the GABAA agonist muscimol and the GABAB agonist baclofen on

52 Microinjections of the GABAA agonist muscimol into PVN inhibit both basal and m

53 To test this, we infused the GABAA agonist muscimol into the IC and the mu-opioid rec

54 Microinjection of the GABAA agonist muscimol into the SCN during the day produ

55 Infusion of the GABAA agonist muscimol into the VM also reduced MCx-SNpr

56 , temporary inactivation of the CeA with the GABAA agonist muscimol reduced DAMGO (D-Ala2-NMe-Phe4-Gl

57 Superfusion of the GABAA agonist muscimol resulted in a decrease of the inp

58 oventricular (ICV) injections of CRH and the GABAA agonist muscimol stimulated locomotor activity.

59 determined whether focal RF infusions of the GABAA agonist muscimol suppressed eating.

60 eas intra-DRN or intra-MRN injections of the GABAA agonist muscimol suppressed this release.

61 We used the GABAA agonist muscimol to inhibit neuronal activation an

62 lex (with either the excitotoxin NMDA or the GABAA agonist muscimol) reduced the ability of morphine

63 The GABAA agonist muscimol, administered either intravenousl

64 of the PFC, with bilateral injections of the GABAA agonist muscimol, selectively blocked the expressi

65 injections of the gamma-aminobutyric acidA (GABAA) agonist muscimol into the nucleus accumbens shell

66 (BLA) or central amygdaloid region (CeA) via GABA(A) agonist (muscimol) infusions and measured feedin

67 -induced motor impairment by intracerebellar GABA(A) agonist (+)-muscimol.

68 The GABA(A) agonist, muscimol, induces phase advances during

69 Microinjection of either a GABA(A) agonist, muscimol, or a GABA(B) agonist, baclofe

70 ction of the gamma-aminobutyric acid type A (GABA(A)) agonist, muscimol, in newborn male and female r

71 The GABAa agonist, muscimol (0.5 microgram in 0.5 microliter

72 llenged with intra-Acb shell infusion of the GABAA agonist, muscimol (10 ng).

73 rogestins and increased central binding of a GABAA agonist, muscimol, compared with that seen in mice

74 The GabaA agonist, muscimol, immediately stimulated release

75 o the RMTg of the gamma-aminobutyric acid A (GABAA) agonist, muscimol, indeed activate locomotion.

76 Muscimol (80 pmol), a GABA(A) agonist, or losartan (43.4 pmol), an AT(1) recep

77 idespread neuronal injury, we found that the GABAA agonists phenobarbital and midazolam significantly

78 eus (AIP) of the cerebellum with muscimol (a GABAA agonist) prevents acquisition of the classically c

79 A series of high-affinity GABA(A) agonists with good oral bioavailability in rat a